Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Sanofi-Aventis 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis

3Q Revenues: $9.9 billion (-2%)

3Q Earnings: $1.9 billion  (-27%)

YTD Revenues: $29.6 billion (-3%)

YTD Earnings: $5.3 billion  (-18%)

Comments: Pharmaceutical sales in the quarter were up 5% to $8.5 billion, driven by the company’s top 15 products. Lovenox sales were $917.5 million (+9%). Plavix sales were $910.3 million (+6%). Lantus sales were $884.3 million (+29%). Taxotere sales were up 17% to $261.5 million. Aprovel sales were up 15% to $430.6 million. Copaxone sales were $144.5 million (+19%). In the U.S., sales of Ambien CR and Ambien IR totaled $177 million and $28 million respectively. Vaccines revenue was $1.4 billion in the quarter (+9%). Flu vaccines were up 10% at $540.4 million. Polio/Pertussis/Hib Vaccines were up 43% to $280.3 million. R&D expenses were flat at $1.6 billion in the quarter (or +4.5% after excluding the effect of exchange rates). In the quarter, the company completed the acquisitions of Acambis (vaccines) and Symbion (nutraceuticals/OTC, Australia). 3Q and YTD results include the unfavorable effect of exchange rates.    

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters